Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2021-01-08 M&A Activity
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
Xlife Sciences AG: Transaction with Baliopharm AG
M&A Activity Classification · 1% confidence The document is an 'Ad-hoc' announcement dated January 8, 2021, disclosing inside information according to MAR Regulation (EU) No 596/2014. The content details a significant 'Transaction with Baliopharm AG' involving a licensing agreement worth up to 300 million euros. This type of announcement, which reports on a major corporate event (a significant licensing deal/transaction) that is not a standard periodic financial report (like 10-K or IR), a management change (MANG), or a director's trade (DIRS), fits best under the general category for significant corporate actions or regulatory disclosures that don't have a more specific code. Since it is a major corporate transaction/agreement, it is not a standard 'Regulatory Filing' (RNS) unless no other category applies. It is not a financing event (CAP), nor is it a merger/takeover (TAR). Given the nature of reporting a major, non-routine corporate agreement/transaction, and lacking a specific 'Corporate Transaction' code, the closest fit among the provided options that covers significant, non-standard corporate news is often the general regulatory/news category. However, since this is a major business transaction (licensing deal), and it is being disclosed as 'inside information' via a regulatory service (DGAP/EQS), it is a significant corporate event disclosure. If we strictly follow the definitions, it is not a standard financial report, management change, or capital event. It is a significant business development. In many filing systems, major business deals fall under a broad 'Material Event' or 'Corporate Transaction' category. Given the options, and noting it is a significant business agreement disclosure, it is most appropriately classified as a general Regulatory Filing (RNS) as it is an ad-hoc disclosure of inside information, or potentially a fallback if it doesn't fit others. Since it is a specific business transaction announcement, and not a standard financial report, RNS is the most appropriate fallback for significant, non-standard disclosures not covered elsewhere. It is not a proxy statement (PSI), dividend notice (DIV), or earnings release (ER).
2021-01-08 English
Xlife Sciences AG: Exit of a project company
Regulatory Filings Classification · 1% confidence The document is a short announcement dated December 23, 2020, classified as 'Ad-hoc' and disclosing 'inside information acc. to Article 17 MAR'. The core content details the successful exit (sale) of a project company stake by Xlife Sciences AG for over 20 million euros. This type of announcement, concerning a significant corporate transaction (divestiture/sale of an investment), does not fit neatly into standard periodic reports (10-K, IR) or specific event reports (ER, DIV, CT). Since it is a material, non-scheduled corporate event disclosure mandated under EU regulations (MAR), and it is not a proxy statement (DEF 14A), director dealing (DIRS), or capital change (CAP/SHA), the most appropriate general category for significant, non-standard corporate news that doesn't fit elsewhere is the Regulatory Filings fallback category (RNS). Given the short length and the nature of the disclosure (a material event update), RNS is the best fit among the provided options, acting as a catch-all for significant, ad-hoc regulatory disclosures.
2020-12-23 English
Xlife Sciences AG: Successful capital raising of six million Swiss francs
Share Issue/Capital Change Classification · 1% confidence The document is a news release announcing that Xlife Sciences AG successfully closed a capital increase, raising 6.02 million Swiss Francs. Key phrases include 'Successful capital raising,' 'Capital Increase,' and 'Key word(s): Capital Increase.' This directly relates to fundraising and changes in the company's capital structure. Based on the definitions, this aligns perfectly with the 'Capital/Financing Update' category.
2020-12-04 English
Xlife Sciences AG: Xlife Sciences expands its project portfolio
Regulatory Filings Classification · 1% confidence The document is a 'News Details' announcement dated December 3, 2020, originating from Xlife Sciences AG, disseminated via DGAP. The content describes a corporate action: the expansion of the project portfolio through the addition of two new project companies (Panmabs GmbH and Xarma Life Science GmbH). This is a general corporate update regarding investments and business development, not a formal financial report (like 10-K or IR), a specific regulatory filing (like DIRS or MRQ), or a transcript. Since it is a general corporate news release announcing business developments that doesn't fit into the more specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate classification is the general regulatory announcement/news category, which is RNS (Regulatory Filings) as per the definition provided, or potentially a general news release category if one existed, but RNS serves as the fallback for miscellaneous regulatory announcements.
2020-12-03 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section detailing 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It specifies the name of the person (Mark Müller), their position ('Member of the administrative or supervisory body'), the nature of the transaction ('Acquisition'), and the details of the shares traded. This content directly matches the definition for Director's Dealing (DIRS).
2020-11-05 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section detailing 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It lists the name of an individual (Oliver R. Baumann), their position ('Member of the managing body'), and details of a transaction (Acquisition of shares) including price, volume, and date. This content directly matches the definition for Director's Dealing (DIRS). The document length is short, but the content is the primary disclosure itself, not an announcement of a separate report.
2020-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.